Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Debt: 2014-2024

Historic Non-Current Debt for Zevra Therapeutics (ZVRA) over the last 6 years, with Dec 2024 value amounting to $59.5 million.

  • Zevra Therapeutics' Non-Current Debt rose 4.08% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $59.5 million for FY2024, which is 1074.58% up from last year.
  • Per Zevra Therapeutics' latest filing, its Non-Current Debt stood at $59.5 million for FY2024, which was up 1,074.58% from $5.1 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Non-Current Debt ranged from a high of $59.5 million in FY2024 and a low of $391,000 during FY2020.
  • Its 3-year average for Non-Current Debt is $25.8 million, with a median of $12.8 million in 2022.
  • In the last 5 years, Zevra Therapeutics' Non-Current Debt slumped by 60.42% in 2023 and then soared by 1,074.58% in 2024.
  • Yearly analysis of 4 years shows Zevra Therapeutics' Non-Current Debt stood at $391,000 in 2020, then reached $12.8 million in 2022, then slumped by 60.42% to $5.1 million in 2023, then surged by 1,074.58% to $59.5 million in 2024.